Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of 4-Guanidino-Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Guanidino-Benzoic Acid SCHEMBL19205978 | 0.93 | CA2 (0.50) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.91 | F2 (0.57) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL10674543 | 0.89 | F2 (0.55) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127093 | 0.89 | F2 (0.55) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL11123754 | 0.89 | F2 (0.55) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL273175 | 0.89 | F2 (0.55) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL28796971 | 0.87 | F2 (0.53) | CA2CA1F2PRSS1PRSS2 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127091 | 0.87 | F2 (0.58) | CA2CA1F2PRSS1PRSS2 | |
| SCHEMBL9717016 | 0.83 | MEN1 (0.56) | ALDH1A1KMT2AMEN1 | |
| 4-Guanidino-Benzoic Acid SCHEMBL9303333 | 0.81 | F2 (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022164150-A1 | NAFAMOSTAT MESYLATE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | (주)국전약품 | 2022-08-04 | — | — | WO | claimed |
| CN-119053164-A | Perovskite solar cell capable of reducing interface defects of electronic layer and preparation method | 西南石油大学 | 2024-11-29 | — | — | CN | disclosed |
| WO-2022164150-A1 | NAFAMOSTAT MESYLATE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | (주)국전약품 | 2022-08-04 | — | — | WO | disclosed |
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
| EP-3016944-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | The California Institute for Biomedical Research (US) | 2016-05-11 | — | — | EP | disclosed |
| CN-105518000-A | Compounds for treatment of cystic fibrosis | CALIFORNIA INST BIOMEDICAL RES | 2016-04-20 | — | — | CN | disclosed |
| WO-2015003083-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-0802179-B1 | SUBSTITUTED AMIDINONAPHTHYL ESTER DERIVATIVES | TORII PHARMACEUTICAL CO LTD (JP) | 2002-08-21 | — | — | EP | disclosed |
| CN-1300303-A | Enzyme inhibitors | PROCTER & GAMBLE (US) | 2001-06-20 | — | — | CN | disclosed |
| US-6211186-B1 | POLYOXYALKYLENE GLYCOL MODIFIED WITH N-HETEROCYCLE DERIVATIVE WITH AMIDINE OR GUANIDINE GROUP; DIAPER RASH, OBESITY, ACNE, PERIODONTAL DISEASE, CONTRACEPTIVES; PROTEASE AND LIPASE INHIBITORS | THE PROCTER & GAMBLE COMPANY | 2001-04-03 | — | — | US | disclosed |
| EP-1062264-A2 | ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6066673-A | COMPOUND CONTAINING A POLYOXYALKYLENE GLYCOL ENCAPPED WITH A GROUP CONTAINING AN AROMATIC CARBOCYCLIC RING HAVING GUANIDINE OR AMIDINE GROUP; USE IN PERSONAL CARE APPLICATIONS ON AN ABSORBENT CARRIER; DIAPER RASH WIPES | THE PROCTER & GAMBLE COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| WO-1999046316-A2 | ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5885990-A | FIBRINOLYSIS PROMOTING ACTION; THROMBOLYSIS ACTION | TORII PHARMACEUTICAL CO., LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0802179-A1 | SUBSTITUTED AMIDINONAPHTHYL ESTER DERIVATIVES | TORII PHARMACEUTICAL CO., LTD. (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5075335-A | Enzyme inhibitors | EISAI CO., LTD. (JP) | 1991-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | F2 1700/4885CA2 2965/4885CA1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.